This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Frattini, M. Articles by Bertario, L. Search for Related Content PubMed PubMed Citation Articles by Frattini, M. Articles by Bertario, L. Related Collections Oncogenesis Oncogenesis: Biomarkers

Cyclooxygenase-2 Expression in FAP Patients Carrying Germ Line MYH Mutations

¹ Department of Experimental Oncology and Unit of Experimental Molecular Pathology; ² Departments of Pathology; ³ Diagnostic and Surgical Endoscopy Unit; ⁴ Preventive-Predictive Medicine Unit; and ⁵ Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori and FIRC Institute of Molecular Oncology, Milan, Italy; and ⁶ Istituto Nazionale Tumori, Genova, Italy

Requests for reprints: Lucio Bertario, Preventive-Predictive Medicine Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via G. Venezian 1, 20133 Milan, Italy. Phone: 39-02-23902549; Fax: 39-02-23902114. E-mail: bertario{at}istitutotumori.mi.it

Familial adenomatous polyposis (FAP) is an autosomal condition caused by inherited mutations in the adenomatous polyposis coli (APC) or in the MYH genes. Clinical trials have established that nonsteroidal anti-inflammatory drugs (NSAID) are effective in preventing the development as well as reducing the size and decreasing the number of adenomas in FAP patients. Our aim was to evaluate the cyclooxygenase-2 (COX-2) expression in surgical specimens from patients with no evidence of germ line APC mutations but carrying germ line MYH mutations. COX-2 expression was evaluated through immunohistochemical and mRNA analysis in carcinomas, adenomas, and healthy mucosa from six patients carrying germ line biallelic MYH mutations. A modulation of COX-2 expression from adenoma (lower level) to carcinoma (higher level) was observed in all patients by both immunohistochemical and mRNA analysis. Moreover, patients with MYH mutations showed a weak COX-2 expression in the whole colorectal mucosa, as for classic FAP patients carrying germ line APC mutations. All together, our data suggest that biallelic MYH patients might benefit from NSAID treatment, because in these patients COX-2 is overexpressed in the whole colorectal mucosa, a finding possibly related to the interplay between COX-2 and APC protein being the APC gene a common target of mutations in MYH patients.

This article has been cited by other articles:

				S. Signoroni, M. Frattini, T. Negri, E. Pastore, E. Tamborini, P. Casieri, M. Orsenigo, L. Da Riva, P. Radice, P. Sala, et al. Cyclooxygenase-2 and Platelet-Derived Growth Factor Receptors as Potential Targets in Treating Aggressive Fibromatosis Clin. Cancer Res., September 1, 2007; 13(17): 5034 - 5040. [Abstract] [Full Text] [PDF]